Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zemaira Clears FDA; Aventis Behring Seeks Distribution Partner

Executive Summary

Aventis Behring is looking externally to boost the sales force for its Zemaira alpha-1 proteinase inhibitor

You may also be interested in...



Zemaira Convention Promotions Omit Risk Information, CBER Letter Says

ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention

Zemaira Convention Promotions Omit Risk Information, CBER Letter Says

ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention

Aventis Divests Behring: CSL Enters Factor VIII Market In $925 Mil. Deal

CSL will enter the U.S. Factor VIII market though its acquisition of Aventis Behring in a deal worth up to $925 mil

Related Content

UsernamePublicRestriction

Register

PS042143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel